Transdermal delivery of antisense compounds

Advanced Drug Delivery Reviews

Volumn 44, Issue 1, 2000, Pages 51-57

  Brand, R M ^a   Iversen, P L ^b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b AVI BIOPHARMA INC   (United States)

Author keywords

Antisense oligonucleotides; Iontophoresis; Skin; Transdermal drug delivery

Indexed keywords

DRUG PRODUCTS; DRUG THERAPY; GENES; PHYSIOLOGICAL MODELS; SKIN;

ANIMAL MODELS; ANTISENSE OLIGONUCLEOTIDES; THERAPEUTIC APPLICATIONS;

CONTROLLED DRUG DELIVERY;

ANTISENSE OLIGONUCLEOTIDE; NUCLEIC ACID BASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGOMER; SUGAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE THERAPY; IONTOPHORESIS; KERATINOCYTE; MOUSE; NONHUMAN; NUDE MOUSE; PASSIVE TRANSPORT; PRIORITY JOURNAL; RAT; SKIN DISEASE; TRANSCYTOSIS;

ADMINISTRATION, CUTANEOUS; ANIMAL; ELECTROPORATION; HUMAN; KERATINOCYTES; OLIGONUCLEOTIDES, ANTISENSE; SKIN;

EID: 0034739603     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00083-1     Document Type: Article

References (36)

1. P. Iversen, Antisense Technologies - Cambridge Healthtech Institute Conference, Idrugs 1 (1998) 538-540.
2. Vlassov V.V., Karamyshev V.N., Yakubov L.A. Penetration of oligonucleotides into mouse organism through mucosa and skin. FEBS Lett. 327:1993;271-274.
3. Vlassov V.V., Nechaeva M.V., Karamyshev V.N., Yakubov L.A. Iontophoretic delivery of oligonucleotide derivatives into mouse tumor. Antisense Res. Dev. 4:1994;291-293.
4. Oldenburg K.R., Vo K.T., Smith G.A., Selick H.E. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J. Pharm. Sci. 84:1995;915-921.
5. Zewert T.E., Pliquett U.F., Langer R., Weaver J.C. Transdermal transport of DNA antisense olignucleotides by electroporation. Biochem. Biophys. Res. Commun. 212:1995;286-292.
6. Yoshida N.H., Roberts M.S. Solute molecular size and transdermal iotophoresis across excised skin. Controlled Release. 25:1993;177-195.
7. Brand R.M., Iversen P.L. Iontophoretic delivery of a telomeric oligonucleotide. Pharm. Res. 13:1996;851-854.
8. Chem T.-L., Miller P.S., Ts'o P.O., Colvin O.M. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single IV injection in mice. Drug Metab. Dispos. 18:1990;815-817.
9. de Smidt P.C., Doan T.L., de Falco S., van Berkel T.J.C. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res. 19:1991;4695-4700.
10. Goodchild J., Zmencick P.C., Kim B. The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits. Antisense Res. Dev. 1:1991;153-160.
11. Lee W.A., Fishback J.A., Shaw J.-P., Bock L.C., Griffin L.C., Cundy K.C. A novel oligodeoxynucleotide inhibitor of thrombin. II. Pharmacokinetics in the cynamologous monkey. Pharmaceut. Res. 12:1995;1943-1947.
12. 14C labeled phosphotothioate oligonucleotide ISIS 2105 after intravenous administration to rats, J. Pharmacol. Exp. Ther. 267 (1993) 1181-1190.
13. 14C labeled phosphotothioate oligonucleotide ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269:1994;89-94.
14. Iversen P.L., Mata J., Tracewell W.G., Zon G. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4:1994;43-52.
15. Zhang R., Yan J., Shahinian H., Am G., Lu Z., Liu T., Saag M.S., Jiang Z., Temsamani J., Martin R.R., Schechter P.J., Agrawal S., Diasio R.B. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58:1995;44-53.
16. Bishop M.R., Iversen P.L., Bayever E., Sharp J.G., Greiner T.C., Copple B.L., Ruddon R., Zon G., Spinolo J., Arneson M., Armitage J.O., Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14:1996;1320-1326.
17. Brand R.M., Wahl A., Iversen P. Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J. Pharm. Sci. 87:1998;49-52.
18. Mata J.E., Joshi S.S., Palen B., Pirruccelo S.J., Jackson J.D., Elias N., Page T., Medlin K.L., Iversen P.L. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharmacol. 144:1997;189-197.
19. Seeberger P.H., Caruthers M.H. Modified oligodeoxynucleotides as antisense therapeutics. Stein C.A., Krieg A.M. Applied Antisense Oligonucleotide Technology. 1998;51-71 Wiley-Liss Inc, USA.
20. Ghosh C., Iversen P.L. Oligonucleotide-induced mutation in cultured cells: characterization, mechanism and implications. Toxicologist. 48:1999;126.
21. Wagner R.W., Matteucci M.D., Lewis J.G., Gutierrez A.J., Moulds C., Froehler B.C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 260:1993;1510-1513.
22. Summerton J., Weller D. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucl. Acid Drug Dev. 7:1997;187-195.
23. Hudziak R.M., Barofsky D., Barofsky D.F., Weller D.L., Huang S.-B., Weller D.D. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucl. Acid Drug Dev. 6:1996;267-272.
24. Stein D., Foster E., Huang S.-B., Weller D.D., Weller J. A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA and phosphorodiamidate DNA. Antisense Nucl. Acid Drug Dev. 7:1997;151-157.
25. Noonberg S.B., Garovoy M.R., Hunt C.A. Characteristics of oligonucleotide uptake in human keratinocyte cultures. J. Invest. Dermatol. 101:1993;727-731.
26. Wigens M., van Hooijdonk C.A., de Jongh G.J., Schalkwijk J., van Erp P.E. Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. Arch. Dermatol. Res. 290:1998;119-125.
27. Nestle F.O., Mitra R.S., Bennett C.F., Chan H., Nickoloff B.J. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol. 103:1994;569-575.
28. Brand R.M., Haase K., Hannah T.L., Iversen P.L. An experimental model for interpreting percutaneous penetration of oligonucleotides that incorporates the role of keratinocytes. J. Invest. Dermatol. 111:1998;1166-1171.
29. Regnier V., Preat V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res. 15:1998;1596-1602.
30. Banga A.K., Bose S., Ghosh T.K. Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharm. 179:1999;1-19.
31. Mitragotri S., Blankschtein D., Langer R. Ultrasound-mediated transdermal protein delivery. Science. 269:1995;850-853.
32. Potts R.O., Mak V.H., Guy R.H., Francoeur M.L. Strategies to enhance permeability via stratum corneum lipid pathways. Adv. Lipid Res. 24:1991;173-210.
33. Menton G.K., Feingold K.R., Mao-Qiang M., Schaude M., Elias P.M. Structural basis for the barrier abnormality following inhibition of HMG CoA reductase in murine epidermis. J. Invest. Dermatol. 98:1992;209-219.
34. Holleran W.M., Ginns E.I., Menon G.K., Grundmann J.-U., Fartasch M., McKinney C.E., Elias P.M., Sidransky E. Consequences of β-glucocerebrosidase deficiency in epidermis. J. Clin. Invest. 93:1994;1756-1764.
35. Desjardins J.P., Iversen P.L. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J. Pharmacol. Exptl. Ther. 275:1995;1608-1613.
36. Brand R.M., Hannah T.L., Iversen P.L. In vivo iontophoretically enhanced transdermal delivery of antisense compounds can alter target enzyme levels in rats. Perspect. Percutan. Penetration. 6A:1998;31.